Bedrijfsoverzicht
aTyr Pharma, Inc. is a clinical stage biotechnology enterprise dedicated to the discovery and development of product candidates that translate tRNA synthetase biology into novel therapies targeting fibrosis and inflammation within the United States. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, a field characterized by high-risk, high-reward research aimed at advancing medical treatments through scientific innovation. As of the latest available data, the entity holds a market capitalization of $81.62M and employs 58 individuals to execute its research and development initiatives. With an annual revenue of $190,000, the company's financial scale indicates a pre-commercialization status typical of early-stage biotechs, where revenue generation is currently negligible compared to the substantial resources required for clinical trials and regulatory approvals.
Financiële gezondheid
The company reported a revenue of $190,000 for the trailing twelve months, while incurring a net income of $-74,118,000 and an EBITDA of $-76,963,000. The substantial disparity between the minimal revenue and the massive negative net income reveals a cost structure dominated by heavy research and development expenditures that far exceed current sales generation. Free cash flow stands at $-33,797,876, indicating that the company is burning through cash reserves to fund its operations and pipeline development rather than generating liquidity from business activities. This negative free cash flow position highlights the company's reliance on external capital sources, such as equity offerings or debt financing, to maintain financial flexibility until product candidates reach commercial viability. Margins reflect the intense burn rate and lack of profitability; the gross margin is 0.0%, the operating margin is -40856.3%, and the profit margin is 0.0%. These margin figures indicate that the company is not yet profitable on a unit basis, with operating costs significantly outweighing gross revenues. The balance sheet shows a cash position of $78.69M against total debt of $12.03M, resulting in a debt-to-equity ratio of 17.88. Despite the high debt-to-equity figure, the absolute debt level is manageable relative to the substantial cash on hand, suggesting a balance sheet that is not overly leveraged in a traditional sense but is heavily weighted toward equity financing. The current ratio is 5.30, which indicates strong short-term liquidity and the ability to meet its short-term obligations with its current assets. Return on Equity is -108.1% and Return on Assets is -51.1%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the asset base.
Waarderingsbeoordeling
Valuation metrics for aTyr Pharma present a complex picture typical of unprofitable biotechnology firms; the P/E Ratio (TTM) is N/A and the Forward P/E is -2.07. The negative forward P/E implies that analysts or models project continued losses or earnings below zero, making traditional price-to-earnings comparisons with profitable peers impossible. The price-to-book ratio is 1.21, indicating that the market values the company at a slight premium of 21% over its book value, reflecting the potential intrinsic value of its intellectual property and clinical pipeline. Alternative valuation measures such as the price-to-sales ratio of 429.57 and an EV/EBITDA of -0.19 suggest that the market is pricing the stock based on speculative future potential rather than current cash flows or earnings power. The 52-week high is $7.29 and the 52-week low is $0.64, meaning the current share price trades within a wide range that reflects high volatility and uncertainty regarding the company's future commercial success. The stock exhibits a beta of 0.65, which suggests that the stock's price volatility is lower than the broader market, moving at roughly 35% less intensity than the market average during periods of fluctuation.
Growth & Income
Growth metrics are unavailable as the company has not yet achieved significant scale, with revenue growth (YoY) and earnings growth (YoY) both listed as N/A. In the absence of growth data, it is impossible to determine if earnings are growing faster or slower than revenue, but the static nature of the current financials indicates a stagnation period prior to major commercial milestones. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings, however negative they may be currently, into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechs but results in an overall growth and income profile that offers no current yield and relies entirely on the successful translation of its tRNA synthetase biology candidates into marketable therapies.